Literature DB >> 27556836

Health Services Utilization, Specialist Care, and Time to Diagnosis with Inflammatory Bowel Disease in Immigrants to Ontario, Canada: A Population-Based Cohort Study.

Eric I Benchimol1, Douglas G Manuel, Nassim Mojaverian, David R Mack, Geoffrey C Nguyen, Teresa To, Astrid Guttmann.   

Abstract

BACKGROUND: Canada has amongst the highest incidence of inflammatory bowel disease (IBD) in the world, and the highest proportion of immigrants among G8 nations. We determined differences in prediagnosis delay, specialist care, health services use, and risk of surgery in immigrants with IBD.
METHODS: All incident cases of IBD in children (1994-2009) and adults (1999-2009) were identified from population-based health administrative data in Ontario, Canada. Linked immigration data identified those who arrived to Ontario after 1985. We compared time to diagnosis, postdiagnosis health services use (IBD specific and related), physician specialist care in immigrants and nonimmigrants, and risk of surgery between immigrants and nonimmigrants.
RESULTS: Thousand two hundred two immigrants were compared with 22,990 nonimmigrants. Immigrants had similar time to diagnosis as nonimmigrants for Crohn's (hazard ratio [HR] 1.002; 95% confidence intervals [CIs] 0.89-1.12) and ulcerative colitis (HR 1.073; 95% CI 0.95-1.21). For outpatient visits, immigrants with IBD were seen by gastroenterologists more often than nonimmigrants. Immigrants had greater IBD-specific outpatient health services use after diagnosis (odds ratio 1.24; 95% CI 1.15-1.33), emergency department visits (odds ratio 1.57, 95% CI 1.30-1.91), and hospitalizations (odds ratio 1.19; 95% CI 1.02-1.40). In immigrants, there was lower risk of surgery for Crohn's (HR 0.66, 95% CI 0.43-0.99) and ulcerative colitis (HR 0.52, 95% CI 0.31-0.87).
CONCLUSIONS: Immigrants to Canada had greater outpatient and specialty care and lower risk of surgery, with no delay in diagnosis, indicating appropriate use of the health system.

Entities:  

Mesh:

Year:  2016        PMID: 27556836     DOI: 10.1097/MIB.0000000000000905

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  11 in total

1.  MS risk in immigrants in the McDonald era: A population-based study in Ontario, Canada.

Authors:  Dalia L Rotstein; Ruth Ann Marrie; Colleen Maxwell; Sima Gandhi; Susan E Schultz; Kinwah Fung; Karen Tu
Journal:  Neurology       Date:  2019-11-05       Impact factor: 9.910

2.  Ethnicity Influences Phenotype and Outcomes in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis of Population-based Studies.

Authors:  Hai Yun Shi; Alexander N Levy; Hirsh D Trivedi; Francis K L Chan; Siew C Ng; Ashwin N Ananthakrishnan
Journal:  Clin Gastroenterol Hepatol       Date:  2017-06-08       Impact factor: 11.382

3.  Familial Consent for Deceased Organ Donation Among Immigrants and Long-term Residents in Ontario, Canada: A Population-Based Retrospective Cohort Study.

Authors:  Alvin Ho-Ting Li; Ahmed A Al-Jaishi; Matthew Weir; Ngan N Lam; Janet Maclean; Sonny Dhanani; S Joseph Kim; Greg Knoll; Amit X Garg
Journal:  Can J Kidney Health Dis       Date:  2017-10-20

4.  Rural and urban disparities in the care of Canadian patients with inflammatory bowel disease: a population-based study.

Authors:  Eric I Benchimol; M Ellen Kuenzig; Charles N Bernstein; Geoffrey C Nguyen; Astrid Guttmann; Jennifer L Jones; Beth K Potter; Laura E Targownik; Christina A Catley; Zoann J Nugent; Divine Tanyingoh; Nassim Mojaverian; Fox E Underwood; Shabnaz Siddiq; Anthony R Otley; Alain Bitton; Matthew W Carroll; Jennifer C deBruyn; Trevor Jb Dummer; Wael El-Matary; Anne M Griffiths; Kevan Jacobson; Desmond Leddin; Lisa M Lix; David R Mack; Sanjay K Murthy; Juan Nicolás Peña-Sánchez; Harminder Singh; Gilaad G Kaplan
Journal:  Clin Epidemiol       Date:  2018-11-08       Impact factor: 4.790

5.  The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization.

Authors:  M Ellen Kuenzig; Eric I Benchimol; Lawrence Lee; Laura E Targownik; Harminder Singh; Gilaad G Kaplan; Charles N Bernstein; Alain Bitton; Geoffrey C Nguyen; Kate Lee; Jane Cooke-Lauder; Sanjay K Murthy
Journal:  J Can Assoc Gastroenterol       Date:  2018-11-02

6.  Cost-effectiveness of faecal calprotectin used in primary care in the diagnosis of inflammatory bowel disease.

Authors:  Wei Zhang; Chiew Hsia Wong; Mallory Chavannes; Tima Mohammadi; Greg Rosenfeld
Journal:  BMJ Open       Date:  2019-04-14       Impact factor: 2.692

7.  Variation in care of patients with elderly-onset inflammatory bowel disease in Ontario, Canada: A population-based cohort study.

Authors:  M Ellen Kuenzig; Therese A Stukel; Gilaad G Kaplan; Sanjay K Murthy; Geoffrey C Nguyen; Robert Talarico; Eric I Benchimol
Journal:  J Can Assoc Gastroenterol       Date:  2020-01-23

Review 8.  Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)-Part 1: Live Vaccines.

Authors:  Eric I Benchimol; Frances Tse; Matthew W Carroll; Jennifer C deBruyn; Shelly A McNeil; Anne Pham-Huy; Cynthia H Seow; Lisa L Barrett; Talat Bessissow; Nicholas Carman; Gil Y Melmed; Otto G Vanderkooi; John K Marshall; Jennifer L Jones
Journal:  J Can Assoc Gastroenterol       Date:  2021-07-29

9.  Asthma is not associated with the need for surgery in Crohn's disease when controlling for smoking status: a population-based cohort study.

Authors:  Gilaad G Kaplan; Eric I Benchimol; M Ellen Kuenzig; Mohsen Sadatsafavi; J Antonio Aviña-Zubieta; Rebecca M Burne; Michal Abrahamowicz; Marie-Eve Beauchamp
Journal:  Clin Epidemiol       Date:  2018-07-12       Impact factor: 4.790

10.  Shifting Health Care Use from Hospitalisations and Surgeries to Outpatient Visits in Children with Inflammatory Bowel Disease: A Population-based Cohort Study from Ontario, Canada.

Authors:  Aman K Dheri; M Ellen Kuenzig; David R Mack; Sanjay K Murthy; Gilaad G Kaplan; Jessy Donelle; Glenys Smith; Eric I Benchimol
Journal:  J Crohns Colitis       Date:  2021-12-18       Impact factor: 9.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.